Serum high-density lipoprotein (HDL) inhibits in vitro enterohemolysin (EHly) activity produced by enteropathogenic Escherichia coli

FEMS Immunology and Medical Microbiology

Volumn 38, Issue 1, 2003, Pages 53-57

  Figueirêdo, Patricia M S ^a   Catani, Cleide F ^a   Yano, Tomomasa ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Enterohemolysin; Escherichia coli; Inhibition; Lipoprotein

Indexed keywords

CHYLOMICRON; ENTEROHEMOLYSIN; ESCHERICHIA COLI PROTEIN; HEMOLYSIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; CATTLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ESCHERICHIA COLI; HEMOLYSIS; HORSE; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; SERUM;

EID: 0142124413     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(03)00125-1     Document Type: Article

References (21)

1. Gordon V.M., Young W.W., Lechler S.M., Leppla S.H., Hewlett E.L. Adenylate cyclase toxins from Bacillus anthracis and Bordetella pertussis: different process for interaction with and into target cells. J. Biol. Chem. 264:1989;14792-14796.
2. Walton J.R., Smith D.H. New hemolysin (τ) produced by Escherichia coli. J. Bacteriol. 98:1969;237-241.
3. Beutin L., Prada J., Zimmermann S., Stephan S., Orskov I., Orskov F. Enterohemolysin, a new type of hemolysin produced by some strains of enteropathogenic E. coli (EPEC). Z.bl. Bacteriol. Hyg. A. 267:1988;576-588.
4. Bhadki S., Mackman N., Nicaud J.M., Holland I.B. Escherichia coli hemolysin may damage target cell membranes by generating transmembranes pores. Infect. Immun. 52:1986;63-69.
5. Bhadki S., Muhly M., Koran S., Schmidt G. Effect of Escherichia coli hemolysin on human monocytes. J. Clin. Invest. 85:1990;1746-1753.
6. Hardardótir I., Grünfeld C. Effects of endotoxin and cytokines on lipid metabolism. Curr. Opin. Lipidol. 5:1994;207-215.
7. Flegel W.A., Wölpl A., Northhoff H., Männel D.N. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect. Immun. 57:1989;2237-2245.
8. Levels J.H., Abraham P.R., Van den Ende A., van Deventer S.J. Distribution and kinetics of lipoprotein-bound endotoxin. Infect. Immun. 69:2001;2821-2828.
9. Moyaeri M., Welch R.A. Effects of the temperature, time, and toxin concentration on lesion formation by the Escherichia coli hemolysin. Infect. Immun. 62:1994;4124-4131.
10. Geoffroy C., Gaillard J.L., Alouf J.E., Berche P. Purification, characterization and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria monocytogenes. Infect. Immun. 55:1987;1641-1646.
11. Redgrave T., Roberts D.C.K., West C.E. Separation of plasma lipoprotein by density-gradient ultracentrifugation. Anal. Biochem. 65:1974;42-49.
12. Jürgens D., Özel M., Takaisi-Kikuni N.B. Production and characterization of Escherichia coli enterohemolysin and its effects on the structure of the erythrocyte membranes. Cell. Biol. Int. 26:2002;175-186.
13. Simons K., Helenius A., Garoff H. Solubilization of the membrane proteins from Semliki Forest virus with Triton X-100. J. Mol. Biol. 80:1973;119-133.
14. Helenius A., Simons K. Solubilization of membrane by detergents. Biochim. Biophys. Acta. 415:1975;29-79.
15. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:1995;211-228.
16. Levine D.M., Parker T.S., Donnelly T.M., Walsh A., Rubin A.L. In vivo protection against endotoxin by plasma high lipoprotein. Proc. Natl. Acad. Sci. USA. 90:1993;12040-12044.
17. Emancipator K., Csako G., Elin R.J. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect. Immun. 60:1992;596-601.
18. Ulevitch R.J., Johnston A.R. The modification of biophysical and endototoxic properties of bacterial lipopolyssacharides by serum. J. Clin. Invest. 62:1978;1313-1324.
19. Ulevitch R.J., Johnston A.R., Westein D.B. New function for high-density lipoproteins. J. Clin. Invest. 67:1981;827-837.
20. Tobias P.S., McAdam K.P.W.J., Soldau K., Ulevitch R.J. Control of lipopolysaccharides by serum. J. Clin. Invest. 62:1985;1313-1324.
21. Pussinen P.J., Metso J., Malle E., Barlage S., Palosuo T., Sattler W., Schimtz G., Jauhiainen M. The role of plasma phospholipid transfers protein (PLTP) in HDL remodeling in acute-phase patients. Biochim. Biophys. Acta. 1533:2001;153-163.